Preclinical models of mesothelioma confirm that specific alterations can lead to different outcomes, for example, CDKN2A loss leads to poor outcomes [56] and BAP1 alterations in combination with NF2 and CDKN2A/B to rapid disease onset [17]. The gene discussed is BAP1; the disease is mesothelioma.